相似文献
1
Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.
Am J Hematol. 2022 Jan 1;97(1):E3-E7. doi: 10.1002/ajh.26380. Epub 2021 Nov 5.
2
Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.
3
A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
Cell Rep Med. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486. eCollection 2022 Jan 18.
4
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
5
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.
6
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
7
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.
J Mol Cell Biol. 2022 Jan 29;13(12):918-920. doi: 10.1093/jmcb/mjab050.
8
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
Nat Med. 2022 Mar;28(3):496-503. doi: 10.1038/s41591-022-01715-4. Epub 2022 Jan 28.
9
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
10
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
mBio. 2021 Jun 29;12(3):e0069621. doi: 10.1128/mBio.00696-21. Epub 2021 Jun 1.
引用本文的文献
1
Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study.
Viruses. 2023 Nov 13;15(11):2250. doi: 10.3390/v15112250.
2
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
3
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
4
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies.
Eur J Intern Med. 2023 Jan;107:7-16. doi: 10.1016/j.ejim.2022.11.009. Epub 2022 Nov 10.
5
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV conserved elements in macaques.
Front Immunol. 2022 Jul 22;13:945706. doi: 10.3389/fimmu.2022.945706. eCollection 2022.
6
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
Front Immunol. 2022 May 25;13:899972. doi: 10.3389/fimmu.2022.899972. eCollection 2022.
7
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.
Biomedicines. 2022 Feb 1;10(2):338. doi: 10.3390/biomedicines10020338.
8
Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis.
Biomedicines. 2022 Jan 18;10(2):204. doi: 10.3390/biomedicines10020204.
9
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece.
Am J Hematol. 2022 Apr;97(4):E147-E150. doi: 10.1002/ajh.26468. Epub 2022 Jan 25.
10
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals.
Hemasphere. 2021 Dec 17;6(1):e677. doi: 10.1097/HS9.0000000000000677. eCollection 2022 Jan.
本文引用的文献
1
Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections.
BMC Med. 2021 Oct 1;19(1):255. doi: 10.1186/s12916-021-02103-4.
2
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.
PLoS Pathog. 2021 Sep 22;17(9):e1009701. doi: 10.1371/journal.ppat.1009701. eCollection 2021 Sep.
3
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.
Cell Rep. 2021 Aug 24;36(8):109570. doi: 10.1016/j.celrep.2021.109570. Epub 2021 Aug 4.
4
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
Science. 2021 Sep 17;373(6561):1372-1377. doi: 10.1126/science.abj4176. Epub 2021 Aug 13.
5
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. doi: 10.1007/s00508-021-01922-y. Epub 2021 Aug 10.
6
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.
Sci Transl Med. 2021 Sep;13(609):eabj0847. doi: 10.1126/scitranslmed.abj0847. Epub 2021 Aug 5.
7
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.
Cell Rep. 2021 Aug 10;36(6):109504. doi: 10.1016/j.celrep.2021.109504. Epub 2021 Jul 23.
8
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.
MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-1062. doi: 10.15585/mmwr.mm7031e2.
9
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
10
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
Zotero 插件